Search research articles
Contact Us
Filters
Showing results (1-10 of 22) with videos related to
Page
of 3
Sort By:
Clinical Drug Investigation
|
September 25, 2013
Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjects
Rajendra H Jani, Kevinkumar Kansagra, Mukul R Jain, et al.
Clinical Pharmacology in Drug Development
|
August 14, 2023
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZY-IL1 in Three Patients with Cryopyrin-Associated Periodic Syndromes
Pravin Hissaria, Kevinkumar Kansagra, Hardik Patel, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|
March 13, 2021
Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study
Anuja Pandit, Nirav Bhalani, B L Shashi Bhushan, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|
July 1, 2021
Corrigendum to "Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study" [International Journal of Infectious Diseases, Volume 105, April 2021, Pages 516-521]
Anuja Pandit, Nirav Bhalani, B L Shashi Bhushan, et al.
Trials
|
May 9, 2026
Study protocol for a randomized, double-blind, placebo-controlled clinical trial of desidustat oral tablet in sickle cell disease: a phase IIa proof-of-concept evaluation
Mayank Gangwar, Gunjan Kumar, Sudipto Roy, et al.
Clinical Pharmacology in Drug Development
|
December 2, 2022
A Food-Effect Study to Evaluate the Oral Bioavailability of Desidustat
Hardik Patel, Taufik Momin, Kevinkumar Kansagra, et al.
Biomedical Chromatography : BMC
|
May 18, 2016
Quantitative determination of saroglitazar, a predominantly PPAR alpha agonist, in human plasma by a LC-MS/MS method utilizing electrospray ionization in a positive mode
Ashok Ghoghari, Ranjeet Dash, Chandrakant Bhatt, et al.
Clinical Therapeutics
|
October 30, 2025
A Novel Metered Dose Inhaler Formulation of Triple-Drug Fixed-Dose Combination of Vilanterol, Glycopyrronium, and Fluticasone Furoate: A Phase III, Randomized, Multicenter Trial to Evaluate the Efficacy and Safety in Indian Patients With Uncontrolled Asthma
Chintan Patel, Diptikant Sahoo, Vaishal Sheth, et al.
Respiratory Medicine
|
August 4, 2025
Efficacy and safety of novel fixed dose combination of vilanterol, glycopyrronium, and fluticasone furoate dry powder inhaler: A phase 3, randomized, non-inferiority trial compared with fixed dose combination of indacaterol, glycopyrronium, and mometasone furoate dry powder inhaler in Indian asthma patients
Chintan Patel, Vaishal Sheth, Ravi Koppula, et al.
Bioanalysis
|
May 11, 2017
A sensitive assay for ZYAN1 in human whole blood and urine utilizing positive LC-MS/MS electrospray ionization
Harilal Patel, Krunal Soni, Rucha Trivedi, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 22) with videos related to
Sort By:
Page
of 3
Clinical Drug Investigation
|
September 25, 2013
Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjects
Rajendra H Jani, Kevinkumar Kansagra, Mukul R Jain, et al.
Clinical Pharmacology in Drug Development
|
August 14, 2023
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZY-IL1 in Three Patients with Cryopyrin-Associated Periodic Syndromes
Pravin Hissaria, Kevinkumar Kansagra, Hardik Patel, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|
March 13, 2021
Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study
Anuja Pandit, Nirav Bhalani, B L Shashi Bhushan, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|
July 1, 2021
Corrigendum to "Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study" [International Journal of Infectious Diseases, Volume 105, April 2021, Pages 516-521]
Anuja Pandit, Nirav Bhalani, B L Shashi Bhushan, et al.
Trials
|
May 9, 2026
Study protocol for a randomized, double-blind, placebo-controlled clinical trial of desidustat oral tablet in sickle cell disease: a phase IIa proof-of-concept evaluation
Mayank Gangwar, Gunjan Kumar, Sudipto Roy, et al.
Clinical Pharmacology in Drug Development
|
December 2, 2022
A Food-Effect Study to Evaluate the Oral Bioavailability of Desidustat
Hardik Patel, Taufik Momin, Kevinkumar Kansagra, et al.
Biomedical Chromatography : BMC
|
May 18, 2016
Quantitative determination of saroglitazar, a predominantly PPAR alpha agonist, in human plasma by a LC-MS/MS method utilizing electrospray ionization in a positive mode
Ashok Ghoghari, Ranjeet Dash, Chandrakant Bhatt, et al.
Clinical Therapeutics
|
October 30, 2025
A Novel Metered Dose Inhaler Formulation of Triple-Drug Fixed-Dose Combination of Vilanterol, Glycopyrronium, and Fluticasone Furoate: A Phase III, Randomized, Multicenter Trial to Evaluate the Efficacy and Safety in Indian Patients With Uncontrolled Asthma
Chintan Patel, Diptikant Sahoo, Vaishal Sheth, et al.
Respiratory Medicine
|
August 4, 2025
Efficacy and safety of novel fixed dose combination of vilanterol, glycopyrronium, and fluticasone furoate dry powder inhaler: A phase 3, randomized, non-inferiority trial compared with fixed dose combination of indacaterol, glycopyrronium, and mometasone furoate dry powder inhaler in Indian asthma patients
Chintan Patel, Vaishal Sheth, Ravi Koppula, et al.
Bioanalysis
|
May 11, 2017
A sensitive assay for ZYAN1 in human whole blood and urine utilizing positive LC-MS/MS electrospray ionization
Harilal Patel, Krunal Soni, Rucha Trivedi, et al.
Page
of 3